BCAX
Bicara Therapeutics Inc. Common Stock
NASDAQ: BCAX · HEALTHCARE · BIOTECHNOLOGY
$21.28
-2.92% today
Updated 2026-04-29
Market cap
$1.40B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.52
Dividend yield
—
52W range
$8 – $24
Volume
0.6M
Bicara Therapeutics Inc. Common Stock (BCAX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | $10000.00 | $19000.00 | $56000.00 | — |
| Gross profit | $-10000.00 | $-19000.00 | $-56000.00 | — |
| Gross margin | — | — | — | — |
| R&D | $31.31M | $30.62M | $63.62M | $125.10M |
| SG&A | $6.34M | $9.27M | $18.77M | $30.51M |
| Operating income | $-37.66M | $-39.89M | $-82.39M | $-155.60M |
| Operating margin | — | — | — | — |
| EBITDA | $-37.72M | $-39.87M | $-82.33M | $-155.60M |
| EBITDA margin | — | — | — | — |
| EBIT | $-37.73M | $-39.89M | $-82.39M | $-155.71M |
| Interest expense | $112000.00 | $0.00 | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-37.84M | $-51.98M | $-68.00M | $-137.95M |
| Net income growth (YoY) | — | -37.4% | -30.8% | -102.9% |
| Profit margin | — | — | — | — |